How AI is supercharging clinical trials

Artificial intelligence (AI) and machine learning are here to stay, so it’s crucial to understand how they can be used to the best effect in the evolving world of clinical trials.

From patient identification and recruitment, to protocol development and design, and to trial monitoring and data analysis, AI can improve the effectiveness of current clinical trials in myriad ways for a variety of stakeholders. As this technology proliferates, those who don’t adopt AI systems, or don’t implement them in the right way, will fall behind their competitors. How can sponsors, investigators, and clinical trial sites best position themselves in this rapidly changing landscape?

In this webinar, brought to you by Syneos Health, experts in clinical trial technology, design, and execution will come together in a moderated discussion to explore these different facets of the opportunities created by AI, both traditional and generative.

Join us on Monday, 5th February at 9am CST, 3pm GMT, 4pm CET as panellists unpack what’s new in the industry, exploring current perspectives surrounding AI and ML in clinical trials, disruptive and incremental use cases, outstanding challenges, and how sponsors can navigate a rapidly advancing technology landscape. This webinar will also explore:

• AI use cases and applications in clinical trials
• Tips, tricks, and things to watch out for in AI implementations
• What could be coming up in the future

Attendees will leave with a better understanding of both the benefits and challenges of AI and ML in clinical research, and how to begin moving forwards in their own organisation.

About the panel

Bob Zambon

Dr Zambon is Vice President, Technology Strategy & Strategic Partnerships, at Syneos Health. In his role, Dr Zambon leads and supports the development and operationalisation of strategic solutions for Syneos Health customers to help address their key R&D and commercial needs by integrating data, technology, analytics, and various partnerships into approaches that accelerate and advance their most important development programs.

Dr Zambon has over twenty years of experience in the life sciences industry, with experience in data science, strategy development, clinical research, product development, sales force training, client management, regulatory affairs, analytics, and market research. He’s led and supported innovative research programmes, including pragmatic, decentralised, and siteless studies, in the areas of cardiology, orthopaedics, immunology, infectious disease, and various medical countermeasures.

Dr Zambon received his PhD in Molecular & Cell Biology at the University of Maryland and his BSc in Biotechnology at Rutgers University.

Terttu Haring, MD

Terttu Haring, MD, is President, Clinical Sites & Patients at Syneos Health. In her role, Dr Haring leads the global clinical operations organisation to drive exceptional delivery, quality, and data integrity for customers, while ensuring a positive experience for sponsors, sites, and patients.

Dr Haring has over 25 years of experience in the clinical development ecosystem, having seen clinical trials from several angles in a research site, large pharma, and CRO setting, including as an investigator and as a research director; by managing local and regional teams in the Netherlands, Europe & Africa; and through overseeing global trial operations and data management activities and pushing digital innovations to clinical operations.

Dr Haring received her MD from Maastricht University in the Netherlands and is based out of the Syneos Health office in Amsterdam.

Jonah Comstock, editor-in-chief at pharmaphorum (moderator), is a veteran digital health journalist. An early hire at MobiHealthNews, he most recently led editorial efforts at HIMSS Media.